Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice.

Autor: Frade-Sosa B; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Salman-Monte TC; Rheumatology Department, Hospital Del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain., Narváez J; Rheumatology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Peralta I; Rheumatology Department, Hospital Universitario Germans Trias I Pujol, Badalona, Spain., Sandoval S; Rheumatology Department, Hospital Vall D'Hebron, Barcelona, Spain., Magallares B; Rheumatology Department, Hospital Santa Creu I Sant Pau, Barcelona, Spain., Heredia S; Rheumatology Department, Hospital Moisès Broggi, Barcelona, Spain., Sapena N; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Riveros-Frutos A; Rheumatology Department, Hospital Universitario Germans Trias I Pujol, Badalona, Spain., Olivé A; Rheumatology Department, Hospital Universitario Germans Trias I Pujol, Badalona, Spain., Corominas H; Rheumatology Department, Hospital Santa Creu I Sant Pau, Barcelona, Spain., Cortés-Hernández J; Rheumatology Department, Hospital Vall D'Hebron, Barcelona, Spain., Gómez-Puerta JA; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Lupus [Lupus] 2024 Apr; Vol. 33 (5), pp. 481-489. Date of Electronic Publication: 2024 Mar 06.
DOI: 10.1177/09612033241237560
Abstrakt: Background: In 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction to SQ BEL therapy in patients previously treated IV BEL. We hypothesized that SQ BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction.
Methods: Observational, multicenter study, conducted in 7 reference centers in Catalonia. We included stable SLE patients (EULAR/ACR 2019) on treatment with SQ BEL and previous use of IV BEL (at least 3 months on IV BEL before switching). Since there are no well-validated tools for SQ BEL treatment satisfaction, we used RASQ-SQ, validated in patients with lymphoma who switched from IV Rituximab to SQ treatment, and modified for BEL treatment.
Results: Twenty-seven patients were included. The more prevalent clinical manifestations observed were related to the skin and joints and the patients had a mean baseline SLEDAI of 2.96 (SD 2.4) and SLICC score of 0.67 (SD 0.88). The median time from treatment with IV BEL before switching to SQ was 21 months (range). 84% of patients reported confidence in SQ BEL. 85.2% felt that treatment with SQ BEL was convenient or very convenient. 85% felt they had gained time with the change. 89% would recommend the SQ injection to other patients. Disease activity (mean SLEDAI) and remission rates remain stable after switching. No major new adverse effects were reported.
Conclusions: Overall satisfaction, satisfaction with via of administration, and satisfaction with the time taken to receive BEL were higher for SQ BEL treatment. A switching SQ strategy is a reasonable alternative for BEL patients.
Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: GSK did not participate either in the design, manuscript preparation or results discussion. BFS received funds from Korean Rheumatology Society for the presentation of this project at Lupus International meeting, Seoul, May 2023. The author has received funding for attending educational courses. TSM received honorariums from GSK for lectures less than US$10.000 per year. JN received honorariums from GSK for lectures less than US$10.000 per year. IP No conflicts of interest for this article. SS No conflicts of interest for this article. BM received honorariums from GSK for lectures less than US$2.000 per year. SH received honorariums from GSK for lectures less than US$10.000 per year. NS No conflicts of interest for this article. ARF No conflicts of interest for this article. AO No conflicts of interest for this article. HC Presentations, collaborations, congress grants, consultancies: Galapagos, Roche, BMS, Fresenius-Kabi, UCB, Pfizer, Novartis, Abbvie, Gebro, Jansen, MSD, AstraZeneca, and Biogen. JCH received honorariums from GSK for lectures less than US$10.000 per year. JAGP received honorariums from GSK for lectures less than US$10.000 per year.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje